A compound of formula, including any stereochemically isomeric form thereof, wherein including any stereochemically isomeric form thereof, wherein A is n is 1; X 1 and X 2 are selected from X 1 is CH and X 2 is CH, or X 1 is N and X 2 is CH, or X 1 is CH and X 2 is N; R 1 is CH 3 or CH 2 CH 3; R 2 is hydrogen, halo or C 1-4 alkyl; R 3 is halo; R 4 is C 1-6 alkyl; C 3-6 cycloalkyl; phenyl; phenyl substituted with 1, 2 or 3 substituents each individually selected from halo, C 1-4 alkyl, C 1-4 alkyloxy, and hydroxy; R 5 is hydrogen or C 1-4 alkyl; R 6 is hydroxy; cyano; C 1-4 alkyl substituted with hydroxy, - -NR 10 R 11 or -O- -NR 10 R 11; - -NR 10 R 11; - -NR 9 -SO 2 -R 8; - -NR 9 - -SO 2 -R 8; - -Heterocycle; - -NR 9 -Heterocycle; -O- -NR 10 R 11; -NR 9 - -C 1-4 alkyl; -NR 9 - -C 3-6 cycloalkyl; -NR 9 - -O-R 8; -NR 9 - -NR 9 -R 8; -NR 9 -SO 2 -R 8; -NR 9 -(P=O)-di(C 1-4 alkyl); -SO 2 -R 8; -SO 2 -NR 10 R 11; -SO 2 -NR 9 - -R 8; or Heteroaryl; R 7 is hydrogen, halo, C 1-4 alkyl or - -NR 10 R 11; R 8 is C 1-4 alkyl, polyhaloC 1-4 alkyl, or C 3-6 cycloalkyl; each R 9 is independently selected from hydrogen or C 1-6 alkyl; R 10 and R 11 are each indepently selected from hydrogen; CN; C 1-4 alkyl; C 3-6 alkenyl; polyhaloC 1-4 alkyl; C 3-6 cycloalkyl; C 3-6 cycloalkyl substituted with C 1-4 alkyl; or C 1-4 alkyl substituted with hydroxy or cyano; Heterocycle is pyrrolidinyl or oxetanyl; and Heteroaryl is 3-oxo-2,3-dihydro-1,2-oxazolyl, or tetrazolyl, wherein each Heteroaryl is optionally substituted with one or two substituents each independently selected from C 1-4 alkyl, halo, amino, and aminocarbonyl; provided that when R 6 is -NR 9 - -C 3-6 cycloalkyl then X 1 is CH and X 2 is CH; or a pharmaceutically acceptable acid addition salt thereof. A is n is 1; X 1 and X 2 are selected from X 1 is CH and X 2 is CH, or X 1 is N and X 2 is CH, or X 1 is CH and X 2 is N; X 1 is CH and X 2 is CH, or X 1 is N and X 2 is CH, or X 1 is CH and X 2 is N; R 1 is CH 3 or CH 2 CH 3; R 2 is hydrogen, halo or C 1-4 alkyl; R 3 is halo; R 4 is C 1-6 alkyl; C 3-6 cycloalkyl; phenyl; phenyl substituted with 1, 2 or 3 substituents each individually selected from halo, C 1-4 alkyl, C 1-4 alkyloxy, and hydroxy; R 5 is hydrogen or C 1-4 alkyl; R 6 is hydroxy; cyano; C 1-4 alkyl substituted with hydroxy, - -NR 10 R 11 or -O- -NR 10 R 11; - -NR 10 R 11; - -NR 9 -SO 2 -R 8; - -NR 9 - -SO 2 -R 8; - -Heterocycle; - -NR 9 -Heterocycle; -O- -NR 10 R 11; -NR 9 - -C 1-4 alkyl; -NR 9 - -C 3-6 cycloalkyl; -NR 9 - -O-R 8; -NR 9 - -NR 9 -R 8; -NR 9 -SO 2 -R 8; -NR 9 -(P=O)-di(C 1-4 alkyl); -SO 2 -R 8; -SO 2 -NR 10 R 11; -SO 2 -NR 9 - -R 8; or cyano; C 1-4 alkyl substituted with hydroxy, - -NR 10 R 11 or -O- -NR 10 R 11; - -NR 10 R 11; - -NR 9 -SO 2 -R 8; - -NR 9 - -SO 2 -R 8; - -Heterocycle; - -NR 9 -Heterocycle; -O- -NR 10 R 11; -NR 9 - -C 1-4 alkyl; -NR 9 - -C 3-6 cycloalkyl; -NR 9 - -O-R 8; -NR 9 - -NR 9 -R 8; -NR 9 -SO 2 -R 8; -NR 9 -(P=O)-di(C 1-4 alkyl); -SO 2 -R 8; -SO 2 -NR 10 R 11; -SO 2 -NR 9 - -R 8; or Heteroaryl; R 7 is hydrogen, halo, C 1-4 alkyl or - -NR 10 R 11; R 8 is C 1-4 alkyl, polyhaloC 1-4 alkyl, or C 3-6 cycloalkyl; each R 9 is independently selected from hydrogen or C 1-6 alkyl; R 10 and R 11 are each indepently selected from hydrogen; CN; C 1-4 alkyl; C 3-6 alkenyl; polyhaloC 1-4 alkyl; C 3-6 cycloalkyl; C 3-6 cycloalkyl substituted with C 1-4 alkyl; or C 1-4 alkyl substituted with hydroxy or cyano; Heterocycle is pyrrolidinyl or oxetanyl; and Heteroaryl is 3-oxo-2,3-dihydro-1,2-oxazolyl, or tetrazolyl, wherein each Heteroaryl is optionally substituted with one or two substituents each independently selected from C 1-4 alkyl, halo, amino, and aminocarbonyl; provided that when R 6 is -NR 9 - -C 3-6 cycloalkyl then X 1 is CH and X 2 is CH; or a pharmaceutically acceptable acid addition salt thereof.